More on BCRX
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $9.11 |
|
|||
| Open | $8.99 | ||||
| 52 Wk High | $10.98 | ||||
| 52 Wk Low | $1.63 | ||||
| Day High | $9.32 | ||||
| Day Low | $8.95 | ||||
| P/E | N/A | ||||
| EPS | $-0.68 | ||||
| Volume | 3,272,762 | ||||
- BioCryst Pharma (BCRX) Reiterated at Market Outperform by Citizens on Orladeyo Potential
- BioCryst names David Jenkins as chief scientific officer
- BioCryst Appoints David W. Jenkins as Chief Scientific Officer
- JPMorgan Resumes BioCryst Pharma (BCRX) at Neutral
- BioCryst Pharma (BCRX) PT Raised to $14 at RBC Capital
- BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- BioCryst Pharma (BCRX) PT Raised to $17 at Jefferies
- Form 8-K BIOCRYST PHARMACEUTICALS For: Jun 25
- BioCryst to close Birmingham lab and shift to external R&D model
- BioCryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility
Entities mentioned with BCRX
- Earnings | View Related Stories »
- FDA | View Related Stories »
- Definitive Agreement | View Related Stories »
- JPMorgan | View Related Stories »
- 13G | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Show More...
